重药控股(000950) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥7,664,345,566.49, representing a decrease of 3.10% compared to ¥7,909,446,755.05 in the same period last year[10] - The net profit attributable to shareholders was ¥84,168,661.88, down 42.45% from ¥146,250,117.11 year-on-year[10] - Basic earnings per share decreased by 37.50% to ¥0.05 from ¥0.08 in the same period last year[10] - The company reported a significant increase in management expenses by 17.48% to ¥170.73 million, reflecting growth in operational scale and personnel costs[32] - The total operating revenue for the current period is 111,034,215.45, compared to 196,367,792.42 in the previous period, indicating a decrease of approximately 43.4%[77] - The net profit for the current period is 95,041,380.02, down from 168,227,190.24 in the previous period, reflecting a decline of about 43.5%[77] - The operating profit decreased to 111,034,215.45 from 196,367,792.42, showing a reduction of approximately 43.4%[77] - The total comprehensive income for the current period is 94,766,380.52, compared to 168,918,530.92 in the previous period, reflecting a decrease of approximately 43.8%[80] Cash Flow - The net cash flow from operating activities was -¥2,027,461,419.24, an increase in outflow of 28.91% compared to -¥1,572,802,104.45 in the previous year[10] - Cash inflow from operating activities totaled 8,035,979,210.47, an increase from 7,130,197,219.15 in the previous period, reflecting a growth of approximately 12.7%[88] - Cash outflow from operating activities was 10,063,440,629.71, up from 8,702,999,323.60, indicating a rise of about 15.6%[91] - Net cash flow from financing activities was 1,765,830,214.01, up from 1,318,501,145.47, reflecting a growth of about 33.9%[94] - Cash and cash equivalents at the end of the period were 1,936,074,300.10, compared to 1,134,114,525.55 in the previous period, showing an increase of approximately 70.7%[94] - Net cash flow from investment activities was -108,470,672.97, an improvement from -491,553,862.09 in the previous period[91] Assets and Liabilities - Total assets at the end of the reporting period were ¥28,443,632,841.40, an increase of 11.63% from ¥25,479,952,289.24 at the end of the previous year[10] - Total liabilities increased to CNY 19,360,446,554.42, up from CNY 16,618,285,302.10, representing a growth of 10.5%[64] - The total current liabilities amounted to CNY 17,500,209,417.57, an increase from CNY 15,193,115,815.29, indicating a rise of 15.2%[64] - The company's long-term equity investments increased to CNY 1,937,039,396.82 from CNY 1,870,080,956.24, showing a growth of approximately 3.6%[58] - The total assets as of March 31, 2020, were CNY 28,443,632,841.40, up from CNY 25,479,952,289.24, representing an increase of about 11.6%[58] Accounts and Inventory - Accounts receivable increased by 15.49% to ¥13.80 billion from ¥11.95 billion at the beginning of the year, attributed to delayed payments from some medical institutions due to the pandemic[25] - The company's inventory rose to CNY 4,476,733,562.07 from CNY 3,763,302,549.25, indicating an increase of around 19.0%[55] - Prepayments rose significantly by 103.46% to ¥740.82 million, driven by increased advance payments for pandemic-related supplies and delays in logistics[27] Government Support and Financial Management - The company received government subsidies amounting to ¥3,776,063.16, primarily from local government awards[10] - The company has established a financial derivatives trading management system to mitigate risks associated with exchange rate fluctuations[43] - The company reported no significant changes in accounting policies for derivatives compared to the previous reporting period[45] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[50] Other Financial Metrics - The company reported a weighted average return on equity of 1.01%, down from 1.78% in the previous year[10] - Financial expenses increased by 29.54% to ¥105.81 million, primarily due to an increase in interest expenses from rising interest-bearing liabilities[32] - Investment income rose by 2.35% to ¥67.55 million, remaining relatively stable compared to the previous year[32] - Research and development expenses decreased to 34,530.54 from 71,104.25, a reduction of approximately 51.4%[76] - Tax expenses decreased to 13,785,231.92 from 23,617,305.08, a decline of about 41.6%[77]